Some people with early-stage cancers may be able to skip surgery after being treated with the immunotherapy drug dostarlimab, ...

Cancer operations that remove whole or parts of an organ can be life-altering. New research suggests that some patients may ...

According to the results of the early study, published simultaneously in the New England Journal of Medicine, 92% of patients ...

A "groundbreaking" cancer treatment trial by Memorial Sloan Kettering shows immunotherapy alone can eliminate some tumors, ...

Neoadjuvant PD-1 blockade with dostarlimab achieved high rates of organ preservation in patients with early-stage mismatch ...

A Ludwig Cancer Research study has identified a specific mode of fat uptake by immune cells within tumors that serves as a metabolic checkpoint against anti-cancer immune responses.

New results from a clinical trial led by Memorial Sloan Kettering Cancer Center (MSK), gastrointestinal oncologists Andrea ...

Learn about a clinical trial that used immunotherapy alone to treat people with several different types of cancer, meaning they did not need to undergo surgery, radiation or chemotherapy.

Bret Hulick was in his second year of medical school at LECOM in Erie, analyzing the case of a 24-year-old colon cancer ...

Dostarlimab effectively eliminates the need for surgery in patients with advanced mismatch repair-deficient (dMMR) tumors, ...

A new implant safely triggers potent immune responses against hard-to-treat cancers showing "promise" for pancreatic and ...